The first in-human study of a new immunotherapy that blocks a natural enzyme that tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life...
The discovery may help explain why sometimes promising immunotherapies designed to help the immune system kill cancer don’t.